• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease.

作者信息

Kang Seong Hee, Lee Hye Won, Yoo Jeong-Ju, Cho Yuri, Kim Seung Up, Lee Tae Hee, Jang Byoung Kuk, Kim Sang Gyune, Ahn Sang Bong, Kim Haeryoung, Jun Dae Won, Choi Joon-Il, Song Do Seon, Kim Won, Jeong Soung Won, Kim Moon Young, Koh Hong, Jeong Sujin, Lee Jin-Woo, Cho Yong Kyun

机构信息

Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.

Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

出版信息

Clin Mol Hepatol. 2021 Jul;27(3):363-401. doi: 10.3350/cmh.2021.0178. Epub 2021 Jun 22.

DOI:10.3350/cmh.2021.0178
PMID:34154309
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8273632/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2996/8273632/30d694af0be0/cmh-2021-0178f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2996/8273632/ff88ed0824d7/cmh-2021-0178f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2996/8273632/30d694af0be0/cmh-2021-0178f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2996/8273632/ff88ed0824d7/cmh-2021-0178f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2996/8273632/30d694af0be0/cmh-2021-0178f2.jpg

相似文献

1
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease.KASL临床实践指南：非酒精性脂肪性肝病的管理
Clin Mol Hepatol. 2021 Jul;27(3):363-401. doi: 10.3350/cmh.2021.0178. Epub 2021 Jun 22.
2
Diagnosis and Management of Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病的诊断与管理
JAMA. 2023 Nov 7;330(17):1687-1688. doi: 10.1001/jama.2023.17935.
3
A REVIEW OF INTERNATIONAL AND NATIONAL CLINICAL GUIDELINES FOR THE DIAGNOSIS AND TREATMENT-OF NONALCOHOLIC FATTY LIVER DISEASE.非酒精性脂肪性肝病诊断与治疗的国际及国内临床指南综述
Eksp Klin Gastroenterol. 2016(11):76-83.
4
NONALCOHOLIC FATTY LIVER DISEASE BRAZILIAN SOCIETY OF HEPATOLOGY CONSENSUS.非酒精性脂肪性肝病巴西肝病学会共识
Arq Gastroenterol. 2016 Apr-Jun;53(2):118-22. doi: 10.1590/S0004-28032016000200013.
5
[An interpretation of European guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease].[欧洲非酒精性脂肪性肝病诊断和治疗指南解读]
Zhonghua Gan Zang Bing Za Zhi. 2016 Jun;24(6):403-5. doi: 10.3760/cma.j.issn.1007-3418.2016.06.002.
6
Diagnosis and Management of Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病的诊断与管理
JAMA. 2018 Dec 18;320(23):2474-2475. doi: 10.1001/jama.2018.17365.
7
[Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)].《代谢功能障碍相关（非酒精性）脂肪性肝病防治指南（2024年版）》
Zhonghua Gan Zang Bing Za Zhi. 2024 May 20;32(5):418-434. doi: 10.3760/cma.j.cn501113-20240327-00163.
8
Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review.当前非酒精性脂肪性肝病筛查、诊断和管理临床指南与实际临床实践之间的差异：有针对性的文献回顾。
Expert Rev Gastroenterol Hepatol. 2021 Nov;15(11):1253-1266. doi: 10.1080/17474124.2021.1974295. Epub 2021 Sep 21.
9
Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China).非酒精性脂肪性肝病防治指南（2018年版，中国）
J Dig Dis. 2019 Apr;20(4):163-173. doi: 10.1111/1751-2980.12685. Epub 2018 Dec 11.
10
Nonalcoholic Fatty Liver Disease: Diagnosis and Management Guidelines From the AACE.非酒精性脂肪性肝病：美国临床内分泌医师协会诊断与管理指南
Am Fam Physician. 2023 May;107(5):554-556.

引用本文的文献

1
Comparison of sarcopenia screening indices using serum creatinine and cystatin C in metabolic dysfunction-associated steatotic liver disease.使用血清肌酐和胱抑素C的肌肉减少症筛查指标在代谢功能障碍相关脂肪性肝病中的比较
Front Med (Lausanne). 2025 Aug 7;12:1633837. doi: 10.3389/fmed.2025.1633837. eCollection 2025.
2
Pathogenesis and management of metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma: a narrative review.代谢功能障碍相关脂肪性肝炎相关肝细胞癌的发病机制与管理：一篇叙述性综述
Ewha Med J. 2024 Oct;47(4):e65. doi: 10.12771/emj.2024.e65. Epub 2024 Oct 31.
3
Chemical profile of Ficus lyrata bark extract and its therapeutic effect on non-alcoholic fatty liver disease via regulating oxidative stress, inflammation and hepatic lipogenesis.

本文引用的文献

1
NASH/Liver Fibrosis Prevalence and Incidence of Nonliver Comorbidities among People with NAFLD and Incidence of NAFLD by Metabolic Comorbidities: Lessons from South Korea.非酒精性脂肪性肝病患者中 NASH/肝纤维化、非肝脏合并症的流行率及代谢合并症与非酒精性脂肪性肝病发病率的相关性：来自韩国的经验。
Dig Dis. 2021;39(6):634-645. doi: 10.1159/000514953. Epub 2021 Feb 3.
2
Direct Comparison of US and MR Elastography for Staging Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.直接比较 US 和 MR 弹性成像在非酒精性脂肪性肝病患者肝纤维化分期中的应用。
Clin Gastroenterol Hepatol. 2022 Apr;20(4):908-917.e11. doi: 10.1016/j.cgh.2020.12.016. Epub 2020 Dec 17.
3
琴叶榕树皮提取物的化学特征及其通过调节氧化应激、炎症和肝脏脂肪生成对非酒精性脂肪性肝病的治疗作用。
BMC Complement Med Ther. 2025 Jul 19;25(1):280. doi: 10.1186/s12906-025-05010-w.
4
Are mesenchymal stem/stromal cells a novel avenue for the treatment of non-alcoholic fatty liver disease?间充质干/基质细胞是治疗非酒精性脂肪性肝病的新途径吗？
World J Stem Cells. 2025 May 26;17(5):99638. doi: 10.4252/wjsc.v17.i5.99638.
5
Impact of cardiometabolic risk factors on hepatic fibrosis and clinical outcomes in MASLD: A population-based multi-cohort study.代谢性心血管危险因素对非酒精性脂肪性肝病相关肝纤维化及临床结局的影响：一项基于人群的多队列研究
JHEP Rep. 2025 Mar 7;7(6):101388. doi: 10.1016/j.jhepr.2025.101388. eCollection 2025 Jun.
6
Cost-effectiveness analysis of MASLD screening using FIB-4 based two-step algorithm in the medical check-up.在体检中使用基于FIB-4的两步算法对代谢相关脂肪性肝病（MASLD）进行筛查的成本效益分析。
Sci Rep. 2025 Jun 2;15(1):19336. doi: 10.1038/s41598-025-01740-6.
7
The association between modified cardiometabolic index with non-alcoholic fatty liver disease and liver fibrosis: a cross-sectional study.改良心脏代谢指数与非酒精性脂肪性肝病及肝纤维化的关联：一项横断面研究。
BMC Gastroenterol. 2025 Apr 17;25(1):265. doi: 10.1186/s12876-025-03876-1.
8
Role of amino acids in the regulation of hepatic gluconeogenesis and lipogenesis in metabolic dysfunctionassociated steatotic liver disease.氨基酸在代谢功能障碍相关脂肪性肝病中对肝脏糖异生和脂肪生成调节中的作用
Clin Mol Hepatol. 2025 Jul;31(3):771-795. doi: 10.3350/cmh.2025.0048. Epub 2025 Apr 16.
9
Hepatocellular Carcinoma and the Role of Liver Transplantation: An Update and Review.肝细胞癌与肝移植的作用：最新进展与综述
J Clin Transl Hepatol. 2025 Apr 28;13(4):327-338. doi: 10.14218/JCTH.2024.00432. Epub 2025 Feb 24.
10
Boron-dipyrromethene Staining May Enhance Fat Detection in the MASLD Zebrafish Model: NGS-validated lncRNA Profiling.硼二吡咯亚甲基染色可能增强MAFLD斑马鱼模型中的脂肪检测：经NGS验证的lncRNA分析
In Vivo. 2025 Mar-Apr;39(2):749-757. doi: 10.21873/invivo.13879.
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
一项安慰剂对照试验评估皮下司美格鲁肽在非酒精性脂肪性肝炎中的疗效。
N Engl J Med. 2021 Mar 25;384(12):1113-1124. doi: 10.1056/NEJMoa2028395. Epub 2020 Nov 13.
4
Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.经活检证实的非酒精性脂肪性肝病的死亡率：一项全国性队列研究的结果。
Gut. 2021 Jul;70(7):1375-1382. doi: 10.1136/gutjnl-2020-322786. Epub 2020 Oct 9.
5
Effects of Statin Use on the Development and Progression of Nonalcoholic Fatty Liver Disease: A Nationwide Nested Case-Control Study.他汀类药物对非酒精性脂肪性肝病发生和进展的影响：一项全国性巢式病例对照研究。
Am J Gastroenterol. 2021 Jan 1;116(1):116-124. doi: 10.14309/ajg.0000000000000845.
6
Effects of Metformin Exposure on Survival in a Large National Cohort of Patients With Diabetes and Cirrhosis.二甲双胍暴露对一个大型全国糖尿病和肝硬化患者队列生存情况的影响。
Clin Gastroenterol Hepatol. 2021 Oct;19(10):2148-2160.e14. doi: 10.1016/j.cgh.2020.08.026. Epub 2020 Aug 13.
7
Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis.美国2型糖尿病患者非酒精性脂肪性肝病筛查具有成本效益：一项全面的成本效用分析。
Gastroenterology. 2020 Nov;159(5):1985-1987.e4. doi: 10.1053/j.gastro.2020.07.050. Epub 2020 Aug 5.
8
Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH.基于证据的临床建议，用于管理 NAFLD 和 NASH 的营养和饮食减肥策略。
Clin Mol Hepatol. 2020 Oct;26(4):383-400. doi: 10.3350/cmh.2020.0067. Epub 2020 Jul 17.
9
Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosis-4 Score.使用Fibrosis-4评分评估的非酒精性脂肪性肝炎伴晚期纤维化患者的医疗保健使用情况和费用
Hepatol Commun. 2020 May 26;4(7):998-1011. doi: 10.1002/hep4.1524. eCollection 2020 Jul.
10
Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis.减重手术可长期解决非酒精性脂肪性肝炎并使肝纤维化消退。
Gastroenterology. 2020 Oct;159(4):1290-1301.e5. doi: 10.1053/j.gastro.2020.06.006. Epub 2020 Jun 15.